DprE1 - from the discovery to the promising tuberculosis drug target

Current Pharmaceutical Design

Volumn 20, Issue 27, 2014, Pages 4379-4403

  Mikušová, Katarína ^a   Makarov, Vadim ^b   Neres, João ^c  

^a Faculty of Natural Sciences   (Slovakia)

^b BACH INSTITUTE OF BIOCHEMISTRY   (Russian Federation)

^c EPFL   (Switzerland)

Author keywords

Benzothiazinones; DprE1; Drug target; Inhibitors; SAR; Structure; Tuberculosis

Indexed keywords

AROMATIC NITRO COMPOUND; BACTERIAL ENZYME; BENZOQUINOXALINE DERIVATIVE; BENZOTHIAZINE DERIVATIVE; BENZOTHIAZINONE DERIVATIVE; BTZ 043; DECAPRENYLPHOSPHORYL BETA DEXTRO RIBOSE; DINITROBENZAMIDE DERIVATIVE; DPRE1 ENZYME; ENZYME INHIBITOR; ETHYL [2 (BENZO[D]THIAZOLE 2 CARBOXAMIDO)THIOPHENE 3 CARBONYL]CARBAMATE; NITROTRIAZOLE DERIVATIVE; RIBOSE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; ALCOHOL DEHYDROGENASE; ARABAN; BACTERIAL PROTEIN; DPRE1 PROTEIN, MYCOBACTERIUM TUBERCULOSIS; POLYSACCHARIDE; THIAZINE DERIVATIVE;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTITUBERCULAR ACTIVITY; AZORHIZOBIUM CAULINODANS; BACTERIAL CELL WALL; BACTERIAL GENETICS; BIOCHEMISTRY; BIOGENESIS; CORYNEBACTERIUM GLUTAMICUM; CRYSTAL STRUCTURE; DRUG MECHANISM; EPIMERIZATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AFRICANUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM MICROTI; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; BINDING SITE; BIOSYNTHESIS; CELL WALL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MICROBIOLOGY; PROCEDURES; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ALCOHOL OXIDOREDUCTASES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BINDING SITES; CELL WALL; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MYCOBACTERIUM TUBERCULOSIS; POLYSACCHARIDES; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84904720492     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282027140630122724     Document Type: Review

References (177)

1. Gould IM. The epidemiology of antibiotic resistance. Int J Antimicrob Agents 2008; 32 Suppl 1: S2-9.
2. Chao MC, Rubin EJ. Letting sleeping dos lie: does dormancy play a role in tuberculosis? Annu Rev Microbiol 2010; 64: 293-311.
3. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-90.
4. Muller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet 2013; 29:160-9.
5. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-66.
6. Velayati AA, Masjedi MR, Farnia P, et al. Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran. Chest 2009; 136: 420-5.
7. Udwadia ZF. Totally drug-resistant tuberculosis in India: who let the djinn out? Respirology 2012; 17: 741-2.
8. Global TB Report 2012. WHO. Geneva, Switzerland 2012. Available at http://www.who.int/tb/publications/global_report/gtbr12_main.pdf. [Accessed 15 February 2013].
9. TB facts: World TB. Available from: http://www.tbfacts.org/global-tb.html. [Accessed 15 February 2013].
10. FDA News Release 31.12.2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm333695.htm. [Accessed 15 February 2013].
11. Voelker R. MDR-TB has new drug foe after fast-track approval. JAMA 2013; 309: 430.
12. Cohen J. Infectious disease. Approval of novel TB drug celebrated--with restraint. Science 2013; 339: 130.
13. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
14. Koul A, Dendouga N, Vergauwen K, et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007; 3: 323-4.
15. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-80.
16. Abrahams KA, Cox JAG, Spivey VL, et al. Identification of Novel Imidazo 1,2-a pyridine Inhibitors Targeting M. tuberculosisQcrB. Plos One 2012; 7: e52951. doi:10.1371/journal.pone.0052951
17. Barry CE, 3rd, Blanchard JS. The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol 2010; 14: 456-66.
18. Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A. Advancing the development of tuberculosis therapy. Nat Rev Drug Discov 2012; 11: 171-2.
19. Villemagne B, Crauste C, Flipo M, Baulard AR, Deprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur J Med Chem 2012; 51: 1-16.
20. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitroand in mice. Plos Med 2006; 3: 2131-44.
21. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405: 962-6.
22. Manjunatha U, Boshoff HI, Barry CE. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2009; 2: 215-8.
23. Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosisby intracellular NO release. Science 2008; 322: 1392-5.
24. Manjunatha UH, Boshoff H, Dowd CS, et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006; 103: 431-6.
25. Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Med Chem 2011; 3: 1427-54.
26. Lee RE, Protopopova M, Crooks E, Slayden RA, Terrot M, Barry CE, 3rd. Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates. J Comb Chem 2003; 5: 172-87.
27. Protopopova M, Hanrahan C, Nikonenko B, et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 2005; 56: 968-74.
28. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE, 3rd. The transcriptional responses of Mycobacterium tuberculosisto inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004; 279: 40174-84.
29. Tahlan K, Wilson R, Kastrinsky DB, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 1797-809.
30. Grzegorzewicz AE, Pham H, Gundi VA, et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat Chem Biol 2012; 8: 334-41.
31. Stanley SA, Grant SS, Kawate T, et al. Identification of novel inhibitors of M. tuberculosisgrowth using whole cell based highthroughput screening. ACS Chem Biol 2012; 7: 1377-84.
32. La Rosa V, Poce G, Canseco JO, et al. MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212. Antimicrob Agents Chemother 2012; 56: 324-31.
33. Makarov V, Manina G, Mikusova K, et al. Benzothiazinones kill Mycobacterium tuberculosisby blocking arabinan synthesis. Science 2009; 324: 801-4.
34. Christophe T, Jackson M, Jeon HK, et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. Plos Pathog 2009; 5: e1000645. doi:10.1371/journal.ppat.1000645
35. Magnet S, Hartkoorn RC, Szekely R, et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 2010; 90: 354-60.
36. Wang F, Sambandan D, Halder R, et al. Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. Proc Natl Acad Sci USA 2013; 110: E2510-7.
37. Jarlier V, Nikaido H. Mycobacterial cell wall: structure and role in natural resistance to antibiotics. FEMS Microbiol Lett 1994; 123: 11-8.
38. Barry CE, Crick DC, McNeil MR. Targeting the formation of the cell wall core of M. tuberculosis. Infect Disord Drug Targets 2007; 7: 182-202.
39. Silver LL. Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 2007; 6: 41-55.
40. Mikusova K, Slayden RA, Besra GS, Brennan PJ. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol. Antimicrob Agents Chemother 1995; 39: 2484-9.
41. Chatterjee D, Hunter SW, McNeil M, Brennan PJ. Lipoarabinomannan. Multiglycosylated form of the mycobacterial mannosylphosphatidylinositols. J Biol Chem 1992; 267: 6228-33.
42. Fukuda T, Matsumura T, Ato M, et al. Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of mycobacteria and pathogenesis of tuberculosis. MBio 2013; 4: e00472-12. doi:10.1128/mBio.00472-12.
43. Kaur D, McNeil MR, Khoo KH, et al. New insights into the biosynthesis of mycobacterial lipomannan arising from deletion of a conserved gene. J Biol Chem 2007; 282: 27133-40.
44. Mishra AK, Driessen NN, Appelmelk BJ, Besra GS. Lipoarabinomannan and related glycoconjugates: structure, biogenesis and role in Mycobacterium tuberculosisphysiology and host-pathogen interaction. FEMS Microbiol Rev 2011; 35: 1126-57.
45. Kanetsuna F, Imaeda T, San Blas F. Chemical analyses of the cell wall of the murine leprosy bacillus. J Bacteriol 1968; 96: 860-1.
46. Wietzerbin J, Das BC, Petit JF, Lederer E, Leyh-Bouille M, Ghuysen JM. Occurrence of D-alanyl-(D)-meso-diaminopimelic acid and meso-diaminopimelyl-meso-diaminopimelic acid interpeptide linkages in the peptidoglycan of Mycobacteria. Biochemistry 1974; 13: 3471-6.
47. McNeil M, Wallner SJ, Hunter SW, Brennan PJ. Demonstration that the galactosyl and arabinosyl residues in the cell-wall arabinogalactan of Mycobacterium lepraeand Mycobacterium tuberculosisare furanoid. Carbohydr Res 1987; 166: 299-308.
48. Bhamidi S, Scherman MS, Rithner CD, et al. The identification and location of succinyl residues and the characterization of the interior arabinan region allow for a model of the complete primary structure of Mycobacterium tuberculosismycolyl arabinogalactan. J Biol Chem 2008; 283: 12992-3000.
49. Bhamidi S, Scherman MS, Jones V, et al. Detailed structural and quantitative analysis reveals the spatial organization of the cell walls of in vivogrown Mycobacterium lepraeand in vitrogrown Mycobacterium tuberculosis. J Biol Chem 2011; 286: 23168-77.
50. Alderwick LJ, Radmacher E, Seidel M, et al. Deletion of Cg-emb in corynebacterianeae leads to a novel truncated cell wall arabinogalactan, whereas inactivation of Cg-ubiAresults in an arabinan-deficient mutant with a cell wall galactan core. J Biol Chem 2005; 280: 32362-71.
51. Daffe M, Brennan PJ, McNeil M. Predominant structural features of the cell wall arabinogalactan of Mycobacterium tuberculosisas revealed through characterization of oligoglycosyl alditol fragments by gas chromatography/mass spectrometry and by 1 H and 13 C NMR analyses. J Biol Chem 1990; 265: 6734-43.
52. McNeil M, Daffe M, Brennan PJ. Evidence for the nature of the link between the arabinogalactan and peptidoglycan of mycobacterial cell walls. J Biol Chem 1990; 265: 18200-6.
53. Mahapatra S, Scherman H, Brennan PJ, Crick DC. N Glycolylation of the nucleotide precursors of peptidoglycan biosynthesis of Mycobacteriumspp. is altered by drug treatment. J Bacteriol 2005; 187: 2341-7.
54. Mahapatra S, Yagi T, Belisle JT, et al. Mycobacterial lipid II is composed of a complex mixture of modified muramyl and peptide moieties linked to decaprenyl phosphate. J Bacteriol 2005; 187: 2747-57.
55. Barry CE, Lee RE, Mdluli K, et al. Mycolic acids: Structure, biosynthesis and physiological functions. Prog Lipid Res 1998; 37: 143-79.
56. McNeil M, Daffe M, Brennan PJ. Location of the mycolyl ester substituents in the cell walls of mycobacteria. J Biol Chem 1991; 266: 13217-23.
57. Zuber B, Chami M, Houssin C, Dubochet J, Griffiths G, Daffe M. Direct visualization of the outer membrane of mycobacteria and corynebacteria in their native state. J Bacteriol 2008; 190: 5672-80.
58. Hoffmann C, Leis A, Niederweis M, Plitzko JM, Engelhardt H. Disclosure of the mycobacterial outer membrane: cryo-electron tomography and vitreous sections reveal the lipid bilayer structure. Proc Natl Acad Sci USA 2008; 105: 3963-7.
59. Minnikin DE. Lipids: complex lipids, their chemistry, biosynthesis and roles. In: Ratledge C, Stanford J, Eds. The biology of the mycobacteria. London: Academic Press 1982; pp. 95-184.
60. Puech V, Chami M, Lemassu A, et al. Structure of the cell envelope of corynebacteria: importance of the non-covalently bound lipids in the formation of the cell wall permeability barrier and fracture plane. Microbiology 2001; 147: 1365-82.
61. Nikaido H, Kim SH, Rosenberg EY. Physical organization of lipids in the cell wall of Mycobacterium chelonae. Mol Microbiol 1993; 8: 1025-30.
62. Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosisfrom the complete genome sequence. Nature 1998; 393: 537-44.
63. JVCI: Comprehensive Microbial Resource-Genomes. Available from: http://cmr.jcvi.org/cgi-bin/CMR/shared/Genomes.cgi. [Accessed 15 February 2013]
64. Pelicic V, Jackson M, Reyrat JM, Jacobs WR, Jr., Gicquel B, Guilhot C. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 1997; 94: 10955-60.
65. Jackson M, Crick DC, Brennan PJ. Phosphatidylinositol is an essential phospholipid of mycobacteria. J Biol Chem 2000; 275: 30092-9.
66. Dhiman RK, Schulbach MC, Mahapatra S, et al. Identification of a novel class of omega, E, E-farnesyl diphosphate synthase from Mycobacterium tuberculosis. J Lipid Res 2004; 45: 1140-7.
67. Triccas JA, Parish T, Britton WJ, Gicquel B. An inducible expression system permitting the efficient purification of a recombinant antigen from Mycobacterium smegmatis. FEMS Microbiol Lett 1998; 167: 151-6.
68. Jin Y, Xin Y, Zhang W, Ma Y. Mycobacterium tuberculosis Rv1302 and Mycobacterium smegmatisMSMEG_4947 have WecA function and MSMEG_4947 is required for the growth of M. smegmatis. FEMS Microbiol Lett 2010; 310: 54-61.
69. Mills JA, Motichka K, Jucker M, et al. Inactivation of the mycobacterial rhamnosyltransferase, which is needed for the formation of the arabinogalactan-peptidoglycan linker, leads to irreversible loss of viability. J Biol Chem 2004; 279: 43540-6.
70. Mikusova K, Mikus M, Besra GS, Hancock I, Brennan PJ. Biosynthesis of the linkage region of the mycobacterial cell wall. J Biol Chem 1996; 271: 7820-8.
71. Mikusova K, Yagi T, Stern R, et al. Biosynthesis of the galactan component of the mycobacterial cell wall. J Biol Chem 2000; 275: 33890-7.
72. Belanova M, Dianiskova P, Brennan PJ, et al. Galactosyl transferases in mycobacterial cell wall synthesis. J Bacteriol 2008; 190: 1141-5.
73. Mikusova K, Belanova M, Kordulakova J, et al. Identification of a novel galactosyl transferase involved in biosynthesis of the mycobacterial cell wall. J Bacteriol 2006; 188: 6592-8.
74. Kremer L, Dover LG, Morehouse C, et al. Galactan biosynthesis in Mycobacterium tuberculosis. Identification of a bifunctional UDPgalactofuranosyltransferase. J Biol Chem 2001; 276: 26430-40.
75. Rose NL, Completo GC, Lin SJ, McNeil M, Palcic MM, Lowary TL. Expression, purification, and characterization of a galactofuranosyltransferase involved in Mycobacterium tuberculosisarabinogalactan biosynthesis. J Am Chem Soc 2006; 128: 6721-9.
76. Weston A, Stern RJ, Lee RE, et al. Biosynthetic origin of mycobacterial cell wall galactofuranosyl residues. Tuber Lung Dis 1997; 78: 123-31.
77. Alderwick LJ, Seidel M, Sahm H, Besra GS, Eggeling L. Identification of a novel arabinofuranosyltransferase (AftA) involved in cell wall arabinan biosynthesis in Mycobacterium tuberculosis. J Biol Chem 2006; 281: 15653-61.
78. Seidel M, Alderwick LJ, Birch HL, Sahm H, Eggeling L, Besra GS. Identification of a novel arabinofuranosyltransferase AftB involved in a terminal step of cell wall arabinan biosynthesis in Corynebacterianeae, such as Corynebacterium glutamicumand Mycobacterium tuberculosis. J Biol Chem 2007; 282: 14729-40.
79. Birch HL, Alderwick LJ, Bhatt A, et al. Biosynthesis of mycobacterial arabinogalactan: identification of a novel α-(1→3) arabinofuranosyltransferase. Mol Microbiol 2008; 69: 1191-206.
80. Skovierova H, Larrouy-Maumus G, Zhang J, et al. AftD, a novel essential arabinofuranosyltransferase from mycobacteria. Glycobiology 2009; 19: 1235-47.
81. Escuyer VE, Lety MA, Torrelles JB, et al. The role of the embA and embBgene products in the biosynthesis of the terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan. J Biol Chem 2001; 276: 48854-62.
82. Berg S, Kaur D, Jackson M, Brennan PJ. The glycosyltransferases of Mycobacterium tuberculosis-roles in the synthesis of arabinogalactan, lipoarabinomannan, and other glycoconjugates. Glycobiology 2007; 17: 35-56R.
83. Mikusova K, Huang H, Yagi T, et al. Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 2005; 187: 8020-5.
84. Goodfellow M, Weaver CR, Minnikin DE. Numerical classification of some Rhodococci, Corynebacteria and related organisms. J Gen Microbiol 1982; 128: 731-45.
85. Collins MD, Smida J, Dorsch M, Stackebrandt E. Tsukamurella gen. nov. harboring Corynebacterium paurometabolumand Rhodococcus aurantiacus. Int J Syst Bacteriol 1988; 38: 385-391.
86. Mergaert P, Van Montagu M, Prome JC, Holsters M. Three unusual modifications, a D-arabinosyl, an N-methyl, and a carbamoyl group, are present on the Nod factors of Azorhizobium caulinodansstrain ORS571. Proc Natl Acad Sci USA 1993; 90: 1551-5.
87. Galbraith L, Wilkinson SG. Structures of the O21 and O25 antigens of Stenotrophomonas maltophilia. Carbohydr Res 2000; 323: 98-102.
88. De Castro C, De Castro O, Molinaro A, Parrilli M. Structural determination of the O-chain polysaccharide from Agrobacterium tumefaciens, strain DSM 30205. Eur J Biochem 2002; 269: 2885-8.
89. Voisin S, Kus JV, Houliston S, et al. Glycosylation of Pseudomonas aeruginosastrain Pa5196 type IV pilins with mycobacterium-like α-1,5-linked d-Arafoligosaccharides. J Bacteriol 2007; 189: 151-9.
90. Wang YL, Li L, Cheng XC, Lu YX, Zhang QL. Structure of a polysaccharide from Urtica fissadetermined by NMR spectra. J Asian Nat Prod Res 2012; 14: 592-5.
91. Pieper S, Unterieser I, Mann F, Mischnick P. A new arabinomannan from the cell wall of the chlorococcal algae Chlorella vulgaris. Carbohydr Res 2012; 352: 166-76.
92. Masucci P, McAlpine IL, Glenn JT. Biochemical studies of bacterial derivatives. XII. The preparation of human tubercle bacillus polysaccharide MB-200 and some of its biological properties. Am Rev Tuberc 1930; 22: 669-77.
93. Chargaff E, Schaefer W. A specific polysaccharide from the Bacillus Calmette-Guerin (BCG). J Biol Chem 1935; 112: 393-405.
94. Hunter SW, Gaylord H, Brennan PJ. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. J Biol Chem 1986; 261: 12345-51.
95. Roberts EG, Anderson RJ. The chemistry of the lipoids of tubercle bacilli: XXII. Concerning the carbohydrates of the purified wax. J Biol Chem 1931; 90: 33-43.
96. Haworth N, Kent PW, Stacey M. The constitution of a lipoidbound polysaccharide from M. tuberculosis, human strain. J Chem Soc 1948; 10: 1220-4.
97. Haworth N, Kent PW, Stacey M. The constitution of a specific somatic polysaccharide from M. tuberculosis, human strain. J Chem Soc 1948; 10: 1211-20.
98. Misaki A, Ikawa N, Kotani S, Kato T. Cell wall arabinogalactan of Mycobacterium phlei. Biochim Biophys Acta 1970; 215: 405-8.
99. Misaki A, Seto N, Azuma I. Structure and immunological properties of D-arabino-D-galactans isolated from cell walls of Mycobacteriumspecies. J Biochem 1974; 76: 15-27.
100. McNeil MR, Brennan PJ. Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information. Res Microbiol 1991; 142: 451-63.
101. Peltier P, Belanova M, Dianiskova P, et al. Synthetic UDPfuranoses as potent inhibitors of mycobacterial galactan biogenesis. Chem Biol 2010; 17: 1356-66.
102. Wolucka BA, McNeil MR, de Hoffmann E, Chojnacki T, Brennan PJ. Recognition of the lipid intermediate for arabinogalactan/arabinomannan biosynthesis and its relation to the mode of action of ethambutol on mycobacteria. J Biol Chem 1994; 269: 23328-35.
103. Wolucka BA, de Hoffmann E. The presence of β-d-ribosyl-1-monophosphodecaprenol in mycobacteria. J Biol Chem 1995; 270: 20151-5.
104. Dabbs ER, Yazawa K, Mikami Y, et al. Ribosylation by mycobacterial strains as a new mechanism of rifampin inactivation. Antimicrob Agents Chemother 1995; 39: 1007-9.
105. Wieland F. Structure and biosynthesis of prokaryotic glycoproteins. Biochimie 1988; 70: 1493-504.
106. Hook M, Lindahl U, Backstrom G, Malmstrom A, Fransson L. Biosynthesis of heparin. 3. Formation of iduronic acid residues. J Biol Chem 1974; 249: 3908-15.
107. Pindar DF, Bucke C. The biosynthesis of alginic acid by Azotobacter vinelandii. Biochem J 1975; 152: 617-22.
108. Scherman M, Weston A, Duncan K, et al. Biosynthetic origin of mycobacterial cell wall arabinosyl residues. J Bacteriol 1995; 177: 7125-30.
109. Kindel PK, Watson RR. Synthesis, characterization and properties of uridine 5'-(α-D-apio-D-furanosyl pyrophosphate). Biochem J 1973; 133: 227-41.
110. Shibaev VN. Biosynthesis of bacterial polysaccharide chains composed of repeating units. Adv Carbohydr Chem Biochem 1986; 44: 277-339.
111. Scherman MS, Kalbe-Bournonville L, Bush D, Xin Y, Deng L, McNeil M. Polyprenylphosphate-pentoses in mycobacteria are synthesized from 5-phosphoribose pyrophosphate. J Biol Chem 1996; 271: 29652-8.
112. Klutts JS, Hatanaka K, Pan YT, Elbein AD. Biosynthesis of darabinose in Mycobacterium smegmatis: specific labeling from dglucose. Arch Biochem Biophys 2002; 398: 229-39
113. Rush JS, Alaimo C, Robbiani R, Wacker M, Waechter CJ. A novel epimerase that converts GlcNAc-P-P-undecaprenol to GalNAc-PP-undecaprenol in Escherichia coliO157. J Biol Chem 2010; 285: 1671-80.
114. Mergaert P, D'Haeze W, Fernandez-Lopez M, et al. Fucosylation and arabinosylation of Nod factors in Azorhizobium caulinodans: involvement of nolK, nodZas well as noeC and/or downstream genes. Mol Microbiol 1996; 21: 409-19.
115. D'Haeze W, Holsters M. Nod factor structures, responses, and perception during initiation of nodule development. Glycobiology 2002; 12: 79R-105R.
116. Lorquin J, Lortet G, Ferro M, et al. Nod factors from Sinorhizobium saheliand S. terangabv. sesbaniaeare both arabinosylated and fucosylated, a structural feature specific to Sesbania rostratasymbionts. Mol Plant Microbe Interact 1997; 10: 879-90.
117. Huang H, Scherman MS, D'Haeze W, et al. Identification and active expression of the Mycobacterium tuberculosisgene encoding 5-phospho-α-d-ribose-1-diphosphate: decaprenylphosphate 5-phosphoribosyltransferase, the first enzyme committed to decaprenylphosphoryl-d-arabinose synthesis. J Biol Chem 2005; 280: 24539-43.
118. Belanger AE, Inamine JM. Genetics of cell wall biosythesis. In: Hatfull GF, Jacobs Jr WR, Eds. Molecular genetics of mycobacteria. Washington, D.C.: ASM Press 2000; pp. 191-202.
119. Trefzer C, Skovierova H, Buroni S, et al. Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-Dribofuranose 2'-oxidase DprE1. J Am Chem Soc 2012; 134: 912-5.
120. Liav A, Ciepichal E, Swiezewska E, et al. Stereoselective syntheses of heptaprenylphosphoryl β-d-arabino-and β-d-ribofuranoses. Tetrahedron Lett. 2009; 50: 2242-4.
121. Liav A, Swiezewska E, Ciepichal E, Brennan PJ. Stereoselectivity in the synthesis of polyprenylphosphoryl β-D-ribofuranoses. Tetrahedron Lett. 2006; 47: 8781-3.
122. Neres J, Pojer F, Molteni E, et al. Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. Sci Transl Med 2012; 4: 150ra121.
123. Sassetti CM, Boyd DH, Rubin EJ. Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 2003; 48: 77-84.
124. Crellin PK, Brammananth R, Coppel RL. Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis. Plos One 2011; 6: e16869. doi: 10.1371/journal.pone.0016869.
125. Wolucka BA. Biosynthesis of D-arabinose in mycobacteria-a novel bacterial pathway with implications for antimycobacterial therapy. FEBS Journal 2008; 275: 2691-711.
126. Meniche X, de Sousa-d'Auria C, Van-Der-Rest B, et al. Partial redundancy in the synthesis of the D-arabinose incorporated in the cell wall arabinan of Corynebacterineae. Microbiology-Sgm 2008; 154: 2315-26.
127. Jiang T, He L, Zhan Y, et al. The effect of MSMEG_6402gene disruption on the cell wall structure of Mycobacterium smegmatis. Microb Pathog 2011; 51: 156-60.
128. Dover LG, Cerdeno-Tarraga AM, Pallen MJ, Parkhill J, Besra GS. Comparative cell wall core biosynthesis in the mycolated pathogens, Mycobacterium tuberculosisand Corynebacterium diphtheriae. FEMS Microbiol Rev 2004; 28: 225-50.
129. Alderwick LJ, Dover LG, Seidel M, et al. Arabinan-deficient mutants of Corynebacterium glutamicumand the consequent flux in decaprenylmonophosphoryl-D-arabinose metabolism. Glycobiology 2006; 16: 1073-81.
130. Seidel M, Alderwick LJ, Sahm H, Besra GS, Eggeling L. Topology and mutational analysis of the single Emb arabinofuranosyltransferase of Corynebacterium glutamicumas a model of Emb proteins of Mycobacterium tuberculosis. Glycobiology 2007; 17: 210-9.
131. Tatituri RV, Alderwick LJ, Mishra AK, et al. Structural characterization of a partially arabinosylated lipoarabinomannan variant isolated from a Corynebacterium glutamicum ubiAmutant. Microbiology 2007; 153: 2621-9.
132. Huang H, Berg S, Spencer JS, et al. Identification of amino acids and domains required for catalytic activity of DPPR synthase, a cell wall biosynthetic enzyme of Mycobacterium tuberculosis. Microbiology 2008; 154: 736-43.
133. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci USA 2002; 99: 3684-9.
134. Kus JV, Kelly J, Tessier L, Harvey H, Cvitkovitch DG, Burrows LL. Modification of Pseudomonas aeruginosaPa5196 type IV Pilins at multiple sites with D-Arafby a novel GT-C family arabinosyltransferase, TfpW. J Bacteriol 2008; 190: 7464-78.
135. Roy PH, Tetu SG, Larouche A, et al. Complete genome sequence of the multiresistant taxonomic outlier Pseudomonas aeruginosa PA7. Plos One 2010; 5: e8842. doi: 10.1371/journal.pone.0008842.
136. Harvey H, Kus JV, Tessier L, Kelly J, Burrows LL. Pseudomonas aeruginosaD-arabinofuranose biosynthetic pathway and its role in type IV pilus assembly. J Biol Chem 2011; 286: 28128-37.
137. Lee KB, De Backer P, Aono T, et al. The genome of the versatile nitrogen fixer Azorhizobium caulinodansORS571. BMC Genomics 2008; 9: 271. doi: 10.1186/1471-2164-9-271
138. Batt SM, Jabeen T, Bhowruth V, et al. Structural basis of inhibition of Mycobacterium tuberculosisDprE1 by benzothiazinone inhibitors. Proc Natl Acad Sci USA 2012; 109: 11354-9.
139. RCSB Protein Data Bank. Avalailable at http://www.pdb.org/pdb/home/home.do. [Accessed 1 March 2013]
140. Li H, Jogl G. Crystal structure of decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium smegmatis. Proteins 2013; 81: 538-43.
141. Forneris F, Heuts DPHM, Delvecchio M, Rovida S, Fraaije MW, Mattevi A. Structural analysis of the catalytic mechanism and stereo selectivity in Streptomyces coelicoloralditol oxidase. Biochemistry 2008; 47: 978-85.
142. Malito E, Coda A, Bilyeu KD, Fraaije MW, Mattevi A. Structures of Michaelis and product complexes of plant cytokinin dehydrogenase: Implications for flavoenzyme catalysis. J Mol Biol 2004; 341: 1237-49.
143. Trefzer C, Rengifo-Gonzalez M, Hinner MJ, et al. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc 2010; 132: 13663-5.
144. Makarov VA, Cole ST, Moellmann U. New benzothiazinone derivatives useful for the treatment of tuberculosis infection or leprosy infection in mammals. WO2007134625-A1. 2007.
145. Makarov V, Moellmann U. New dithiocarbamate derivatives, useful as antibacterial agents, for treating e.g. tuberculosis and infections caused by mycobacteria and staphylococci. WO2003042186-A. 2003.
146. Hogarth G. Metal-dithiocarbamate complexes: chemistry and biological activity. Mini Rev Med Chem 2012; 12: 1202-15.
147. Szolar OHJ. Environmental and pharmaceutical analysis of dithiocarbamates. Anal Chim Acta 2007; 582: 191-200.
148. Makarov V, Riabova OB, Yuschenko A, et al. Synthesis and antileprosy activity of some dialkyldithiocarbamates. J Antimicrob Chemother 2006; 57: 1134-8.
149. Urlyapova NG, Yushchenko AA, Daudova AD, Makarov VA. Study of antileprosy activities of some dialkyldithiocarbamate derivatives. Bull Exp Biol Med 2007; 143: 356-8.
150. Sala C, Dhar N, Hartkoorn RC, et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010; 54: 4150-8.
151. Pasca MR, Degiacomi G, Ribeiro AL, et al. Clinical isolates of Mycobacterium tuberculosisin four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 2010; 54: 1616-8.
152. Lechartier B, Hartkoorn RC, Cole ST. In vitrocombination studies of Benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 5790-3.
153. Manina G, Bellinzoni M, Pasca MR, et al. Biological and structural characterization of the Mycobacterium smegmatisnitroreductase NfnB, and its role in benzothiazinone resistance. Mol Microbiol 2010; 77: 1172-85.
154. Roldan MD, Perez-Reinado E, Castillo F, Moreno-Vivian C. Reduction of polynitroaromatic compounds: the bacterial nitroreductases. FEMS Microbiol Rev 2008; 32: 474-500.
155. Makarov VA. Process for the preparation of 2-amino substituted 1,3-benzothiazine-4-ones. WO 2011132070. 2011.
156. Karoli T, Becker B, Zuegg J, et al. Identification of antitubercular benzothiazinone compounds by ligand-based design. J Med Chem 2012; 55: 7940-4.
157. Cooper M, Zuegg J, Becker B, Karoli T. New benzothiazinone compound useful for treating or preventing a microbial infection e.g. tuberculosis or leprosy infection in mammals. WO 2012085654-A1. 2012.
158. Gao C YT, Wang NY, Zeng XX, et al. Synthesis and structureactivity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. Bioorg Med Chem Lett 2013: doi: 10.1016/j.bmcl.2013.06.069.
159. Yu L, Wey Y. Benzothiazinethione derivatives and their preparative methods and uses. WO 2012162912 A1 2012.
160. Alejandre-Duran E, Claramunt RM, Sanz D, Vilaplana MJ, Molina P, Pueyo C. Study on the mutagenicity of nifurtimox and eight derivatives with the L-arabinose resistance test of Salmonella typhimurium. Mutat Res 1988; 206: 193-200.
161. Zhang Y, Munday R. Dithiolethiones for cancer chemoprevention: where do we stand? Mol Cancer Ther 2008; 7: 3470-9.
162. Ribeiro AL, Degiacomi G, Ewann F, et al. Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. Plos One 2011; 6: e26675. doi: 10.1371/journal.pone.0026675.
163. Chembank Database, Broad Institute. Available at http://chembank.broadinstitute.org/. [Accessed: 1 March 2013].
164. Spain JC. Biodegradation of nitroaromatic compounds. Annu Rev Microbiol 1995; 49: 523-55.
165. Callan HE, Jenkins RE, Maggs JL, et al. Multiple adduction reactions of nitroso sulfamethoxazole with cysteinyl residues of peptides and proteins: implications for hapten formation. Chem Res Toxicol 2009; 22: 937-48.
166. Ellis MK, Hill S, Foster PM. Reactions of nitrosonitrobenzenes with biological thiols: identification and reactivity of glutathion-Syl conjugates. Chem Biol Interact 1992; 82: 151-63.
167. Tiwari R, Moraski GC, Krchnak V, et al. Thiolates Chemically Induce Redox Activation of BTZ043 and Related Potent Nitro Aromatic Anti-Tuberculosis Agents. J Am Chem Soc 2013.
168. Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Future microbiol 2011; 6: 617-33.
169. Alderwick LJ, Lloyd GS, Lloyd AJ, Lovering AL, Eggeling L, Besra GS. Biochemical characterization of the Mycobacterium tuberculosisphosphoribosyl-1-pyrophosphate synthetase. Glycobiology 2011; 21: 410-25.
170. Marques MA, Neves-Ferreira AG, da Silveira EK, et al. Deciphering the proteomic profile of Mycobacterium lepraecell envelope. Proteomics 2008; 8: 2477-91.
171. He Z, De Buck J. Cell wall proteome analysis of Mycobacterium smegmatisstrain MC 2 155. BMC Microbiol 2010; 10: 121. doi: 10.1186/1471-2180-10-121.
172. Bell C, Smith GT, Sweredoski MJ, Hess S. Characterization of the Mycobacterium tuberculosisproteome by liquid chromatography mass spectrometry-based proteomics techniques: a comprehensive resource for tuberculosis research. J Proteome Res 2012; 11: 119-30.
173. Rezwan M, Laneelle MA, Sander P, Daffe M. Breaking down the wall: fractionation of mycobacteria. J Microbiol Methods 2007; 68: 32-9.
174. Larrouy-Maumus G, Skovierova H, Dhouib R, et al. A small multidrug resistance-like transporter involved in the arabinosylation of arabinogalactan and lipoarabinomannan in mycobacteria. J Biol Chem 2012; 287: 39933-41.
175. Thanky NR, Young DB, Robertson BD. Unusual features of the cell cycle in mycobacteria: Polar-restricted growth and the snapping-model of cell division. Tuberculosis 2007; 87: 231-6.
176. PBTZ169 in the TB drug pipeline. Available at: http://www.newtbdrugs.org/project.php?id=145554. [Accessed 30 July 2013]
177. Makarov V, Cole S. New piperazin-1-yl-4H-1,3-benzothiazin-4-one derivatives useful for treating disease caused by a microbial infection, where the: infection is tuberculosis, leprosy or Buruli ulcer; and infection is caused by e.g. Mycobacterium. WO2012066518-A1 2012.